PE20141297A1 - Formulaciones peptidicas robustas de liberacion controlada - Google Patents

Formulaciones peptidicas robustas de liberacion controlada

Info

Publication number
PE20141297A1
PE20141297A1 PE2014000875A PE2014000875A PE20141297A1 PE 20141297 A1 PE20141297 A1 PE 20141297A1 PE 2014000875 A PE2014000875 A PE 2014000875A PE 2014000875 A PE2014000875 A PE 2014000875A PE 20141297 A1 PE20141297 A1 PE 20141297A1
Authority
PE
Peru
Prior art keywords
weight
controlled release
insaturation
acil
chains
Prior art date
Application number
PE2014000875A
Other languages
English (en)
Inventor
Fredrik Tiberg
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47226199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141297(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of PE20141297A1 publication Critical patent/PE20141297A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

SE REFIERE A UNA PREFORMULACION QUE COMPRENDE UNA MEZCLA CRISTALINA NO LIQUIDA DE BAJA VISCOSIDAD DE: A) 25 A 55% EN PESO DE UN DIACILGLICEROL O UN TOCOFEROL; B) 25 A 55% EN PESO DE FOSFOLIPIDOS QUE TIENEN i) GRUPOS DE CABEZA POLAR QUE COMPRENDEN MAS DEL 50% DE FOSFATIDILETANOLAMINA, Y ii) DOS CADENAS DE ACILO DE 16 A 20 CARBONOS DONDE UNA CADENA DE ACILO TIENE UNA INSATURACION Y NO HAY MAS DE CUATRO INSATURACIONES EN LAS DOS CADENAS; C) 5 A 25% EN PESO DE UN SOLVENTE BIOCOMPATIBLE, ORGANICO, DE BAJA VISCOSIDAD Y QUE CONTIENE OXIGENO TAL COMO ETANOL; Y D) DE 0,1 A 10% EN PESO DE UN AGENTE PEPTIDICO ACTIVO QUE COMPRENDE UN AGONISTA DEL RECEPTOR DE SOMATOSTATINA TAL COMO SST-14, OCTREOTIDA, LANREOTIDA, ENTRE OTROS; EN DONDE LA PREFORMULACION FORMA O TIENE LA CAPACIDAD DE FORMAR UNA ESTRUCTURA DE FASE CRISTALINA LIQUIDA NO LAMINAR AL ENTRAR EN CONTACTO CON UN FLUIDO ACUOSO. DICHA COMPOSICION ES UTIL EN LA LIBERACION CONTROLADA DE PEPTIDOS
PE2014000875A 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberacion controlada PE20141297A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161566851P 2011-12-05 2011-12-05

Publications (1)

Publication Number Publication Date
PE20141297A1 true PE20141297A1 (es) 2014-10-09

Family

ID=47226199

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000875A PE20141297A1 (es) 2011-12-05 2012-11-28 Formulaciones peptidicas robustas de liberacion controlada

Country Status (23)

Country Link
US (2) US9585959B2 (es)
EP (2) EP2787975B1 (es)
JP (2) JP6081480B2 (es)
KR (2) KR101979051B1 (es)
CN (2) CN104093399B (es)
AU (2) AU2012348641B2 (es)
BR (2) BR112014013693B1 (es)
CA (2) CA2857982A1 (es)
CL (1) CL2014001472A1 (es)
CO (1) CO7000746A2 (es)
DK (2) DK2787975T3 (es)
EA (2) EA027924B1 (es)
ES (2) ES2645345T3 (es)
HK (2) HK1201722A1 (es)
HR (1) HRP20170954T1 (es)
IL (2) IL232789B (es)
MX (2) MX352024B (es)
PE (1) PE20141297A1 (es)
PL (1) PL2787975T3 (es)
SG (1) SG11201402673YA (es)
SI (1) SI2787974T1 (es)
WO (2) WO2013083460A1 (es)
ZA (1) ZA201403793B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
TWI624271B (zh) * 2011-05-25 2018-05-21 凱慕路斯公司 包含低黏度混合物之預調配物及其形成方法，及該低黏度混合物或預調配物之用途
MX350964B (es) * 2012-05-25 2017-09-27 Camurus Ab Formulaciones de agonistas del receptor de somatostatina.
EP2877155B1 (en) * 2012-07-26 2020-10-28 Camurus AB Opioid formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
AU2014340095A1 (en) 2013-10-22 2016-05-26 Prolynx Llc Conjugates of somatostatin and its analogs
WO2016092569A1 (en) * 2014-12-10 2016-06-16 Council Of Scientific & Industrial Research A discontinuous reverse micellar composition in cubic fd3m phase for sustained release of therapeutic drugs
WO2016102683A1 (en) * 2014-12-23 2016-06-30 Camurus Ab Controlled-release formulations
GB201516554D0 (en) * 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
ITUB20160416A1 (it) * 2016-01-28 2017-07-28 Italfarmaco Spa Uso di una formulazione a lento rilascio di octreotide per la prevenzione della formazione di seroma
CN108883157A (zh) * 2016-03-31 2018-11-23 太阳医药高级研发有限公司 适用于每周一次或每两周一次给药的利拉鲁肽的粘弹性凝胶
CA3036307A1 (en) * 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
CN109789215B (zh) 2016-09-27 2022-12-16 卡姆拉斯公司 含有生长激素抑制素受体激动剂的制剂
US10779576B2 (en) 2017-05-24 2020-09-22 VMR Products, LLC Flavor disk
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3787609A4 (en) * 2018-05-01 2022-01-05 Chibi, Inc. EYE DROP FORMULATION AND PROLONGED METHOD OF DRUG ADMINISTRATION TO THE RETINAL
BR112020022087A2 (pt) 2018-05-01 2021-02-02 Chibi, Inc. depot líquido para liberação prolongada de um agente ativo no olho, conjunto, e, métodos para tratar uma doença ocular em um indivíduo e para prover um revestimento protetor para o olho.
CN108498849B (zh) * 2018-05-08 2021-04-30 武汉百纳礼康生物制药有限公司 一种液晶凝胶肝动脉栓塞剂及其制备方法
CN109091451B (zh) * 2018-09-10 2021-08-13 武汉百纳礼康生物制药有限公司 亲水性药物的油相液晶凝胶前体制剂及其制备方法
CN113993535A (zh) 2019-05-29 2022-01-28 卡姆拉斯公司 脂质控释组合物
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine
US20230372317A1 (en) * 2020-10-27 2023-11-23 Pts Consulting, Llc A liquid injectable composition of donepezil
CN113081954A (zh) * 2021-05-25 2021-07-09 南昌大学第二附属医院 一种凝胶载药贴剂药物输送系统
CN117794519A (zh) * 2021-07-27 2024-03-29 法纳克斯株式会社 非层状液晶形成性组合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8206744D0 (sv) 1982-11-26 1982-11-26 Fluidcarbon International Ab Preparat for kontrollerad avgivning av substanser
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
EP0752855B1 (en) * 1994-03-30 1999-06-09 Gs Development Ab Use of fatty acid esters as bioadhesive substances
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
ATE272394T1 (de) 1996-10-31 2004-08-15 Takeda Chemical Industries Ltd Zubereitung mit verzögerter freisetzung
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
JP3952617B2 (ja) 1998-12-11 2007-08-01 株式会社日立製作所 内燃機関の排ガス浄化装置，排ガス浄化方法及び排ガス浄化触媒
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20080112915A1 (en) * 2003-10-24 2008-05-15 Marianna Foldvari Dna Delivery with Gemini Cationic Surfactants
WO2005046642A1 (en) 2003-11-07 2005-05-26 Camurus Ab Compositions of lipids and cationic peptides
US8182834B2 (en) 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
WO2006002050A1 (en) * 2004-06-15 2006-01-05 Encore Therapeutics, Inc. Phospholipid compositions and methods for their preparation and use
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
PL1843746T3 (pl) * 2005-01-14 2011-09-30 Camurus Ab Formulacje analogów somatostatyny
EP1843751B1 (en) 2005-01-21 2020-09-30 Camurus Ab Pharmaceutical lipid compositions
DK1888031T3 (da) 2005-06-06 2013-02-18 Camurus Ab GLP-1-analogformuleringer
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations

Also Published As

Publication number Publication date
CO7000746A2 (es) 2014-07-21
WO2013083460A1 (en) 2013-06-13
JP2015500253A (ja) 2015-01-05
KR20140111661A (ko) 2014-09-19
EA028040B1 (ru) 2017-09-29
JP6081480B2 (ja) 2017-02-15
JP6081479B2 (ja) 2017-02-15
CN104105479A (zh) 2014-10-15
CN104105479B (zh) 2018-04-10
AU2012348640A1 (en) 2014-07-17
EP2787975B1 (en) 2017-10-04
EP2787974B1 (en) 2017-05-24
AU2012348641B2 (en) 2016-04-21
EA027924B1 (ru) 2017-09-29
US9555118B2 (en) 2017-01-31
ZA201403793B (en) 2017-04-26
CA2858227C (en) 2021-01-05
US9585959B2 (en) 2017-03-07
CL2014001472A1 (es) 2014-11-21
DK2787975T3 (da) 2017-11-20
CA2858227A1 (en) 2013-06-13
EA201490921A1 (ru) 2014-11-28
US20140329749A1 (en) 2014-11-06
WO2013083459A1 (en) 2013-06-13
CA2857982A1 (en) 2013-06-13
US20140348903A1 (en) 2014-11-27
CN104093399B (zh) 2018-03-13
BR112014013693B1 (pt) 2023-01-31
EP2787974A1 (en) 2014-10-15
ES2645345T3 (es) 2017-12-05
DK2787974T3 (en) 2017-07-17
HK1201722A1 (en) 2015-09-11
JP2015505833A (ja) 2015-02-26
BR112014013693A2 (pt) 2020-06-30
EA201491005A1 (ru) 2014-11-28
KR20140105527A (ko) 2014-09-01
AU2012348641A1 (en) 2014-06-19
PL2787975T3 (pl) 2018-01-31
EP2787975A1 (en) 2014-10-15
SG11201402673YA (en) 2014-06-27
HK1201735A1 (en) 2015-09-11
BR112014013691A2 (pt) 2017-06-13
HRP20170954T1 (hr) 2017-09-22
CN104093399A (zh) 2014-10-08
MX2014006625A (es) 2014-09-22
MX352024B (es) 2017-11-07
KR101979051B1 (ko) 2019-05-15
IL232789A0 (en) 2014-07-31
IL232789B (en) 2019-11-28
IL232967A0 (en) 2014-07-31
MX350929B (es) 2017-09-26
SI2787974T1 (sl) 2017-10-30
MX2014006624A (es) 2014-09-22
AU2012348640B2 (en) 2016-07-21
ES2629188T3 (es) 2017-08-07

Similar Documents

Publication Publication Date Title
PE20141297A1 (es) Formulaciones peptidicas robustas de liberacion controlada
CL2013003365A1 (es) Formulacion farmaceutica que comprende diacilglicerol y/o tocoferol, fosfatidilcolina, solvente mono-alcoholico organico biocompatible que comprende etanol, solvente polar, y un analogo de somatostatina como principio activo; proceso para prepararla; kit farmaceutico; uso en el tratamiento de acromegalia y canceres, entre otros.
PH12014502778B1 (en) Antibody formulation
PE20160681A1 (es) Formulacion de premezcla de dexmedetomidina
CL2015001945A1 (es) (divisional de la solicitud n° 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
BR112014010275A2 (pt) formulações para tratamento de diabetes
AR091902A1 (es) Formulacion liquida de un conjugado de insulina de accion prolongada
AR083016A1 (es) Formulaciones liquidas para la agricultura con una mejor estabilidad
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
PH12015502542A1 (en) Stabilized pemetrexed formulation
BR112016006171A2 (pt) formulações de espuma e dispositivo para sua entrega
PE20141068A1 (es) Formulaciones topicas de tipo suspension que comprenden depsipeptido ciclico
AR091530A1 (es) Formulacion farmaceutica liquida de un anticuerpo y acetato
BR112017017643A2 (pt) formulação farmacêutica tópica
PH12014502614A1 (en) Somatostatin receptor agonist formulations
PE20110283A1 (es) Composicion que contiene nifurtimox
AR091526A1 (es) Composicion pesticida en la forma de emulsion acuosa
AR061802A1 (es) Composicion que tiene una actividad que previene la germinacion, procedimientos para obtener dichas composiciones y uso de las mismas
MX2013005306A (es) Composicion farmaceutica.
AR087488A1 (es) Uso de composiciones para retrasar el inicio de la fase catagena del cabello
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
WO2011162560A3 (ko) 난용성 트리사이클릭 유도체 화합물의 용해도가 향상된 약학적 조성물
PE20171305A1 (es) Formulaciones inyectables de paracetamol
AR105504A1 (es) Concentrado que contiene alprostadil

Legal Events

Date Code Title Description
FD Application declared void or lapsed